$0.04

0.003 (8.82%)

General Information

Antisense Therapeutics Limited
ANP
http://www.antisense.com.au
Pharmaceuticals
7
177

Current Price Data+

Current Price $0.037
Open $0.036
High $0.037
Low $0.036
Last Close $0.034
Volume 40000
Price Movement $0.00 ( 8.82% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Stock Price

Company Overview

Business Description

Antisense Therapeutics Limited (ANP) is a biopharmaceutical drug discovery and development company. ANP develops and commercialises second generation antisense pharmaceuticals for unmet markets. ANP has four products including ATL1102 injection for Multiple Sclerosis, ATL1103 injection for growth & sight disorders, ATL1101 injection for prostate cancer, and ATL1102 inhaled for asthma.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2015 A 0.7 0.5 0.0% 25.2 0.0 0.0% 0.0%
2014 A -3.0 -2.1 0.0% 0.0 0.0 0.0% 0.0%
2013 A -2.5 -1.7 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2013 A 2014 F 2015 F 2013 A 2014 F 2015 F 2013 A 2014 F 2015 F
Antisense Therapeutics (ANP) $6M 0.0000 0.0000 0.0000 7.5556 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group (MYX) $1,126M -0.3897 2.1675 0.1008 72.7749 22.9752 20.8709 0.00% 0.00% 0.00%
Starpharma (SPL) $244M 0.0000 0.0000 0.0000 0.0000 0.0000 19.5588 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.61 8.22 0.92 0.00
Market 1.14 15.80 1.16 0.90
Sector 0.49 15.70 3.24 0.69

Directors

Name Position Start Date
Mr Robert William Moses Chairman 23 Oct 2001
Mr Mark P Diamond Chief Executive Officer, Managing Director 31 Oct 2001
Professor Graham Mitchell Non-Executive Director 24 Oct 2001
Dr Gary W Pace Non-Executive Director 9 Nov 2015
Mr William Goolsbee Non-Executive Director 15 Oct 2015

Management

Name Position
Phillip Hains Chief Financial Officer,Company Secretary
George Tachas Director, Drug Discovery & Patents

Substantial Shareholders

Holding Name
15,025,075 (8.51%) Cortendo
14,361,583 (8.12%) Polychip Pharmaceuticals Pty Ltd

Calendar of Events

Date Event
21 February 2017 Report (Interim)
10 October 2016 Report (Annual)
28 September 2016 Report (Annual)
22 August 2016 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.